These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11583478)

  • 1. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    J Clin Pharmacol; 2001 Oct; 41(10):1098-105. PubMed ID: 11583478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine.
    Arasteh K; Wood R; Müller M; Prince W; Cass L; Moore KH; Dallow N; Jones A; Klein A; Burt V; Kleim JP
    HIV Clin Trials; 2001; 2(4):307-16. PubMed ID: 11590533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers.
    Cass LM; Moore KH; Dallow NS; Jones AE; Sisson JR; Prince WT
    J Clin Pharmacol; 2001 May; 41(5):528-35. PubMed ID: 11361049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
    Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
    Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
    Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers.
    Eiznhamer DA; Creagh T; Ruckle JL; Tolbert DT; Giltner J; Dutta B; Flavin MT; Jenta T; Xu ZQ
    HIV Clin Trials; 2002; 3(6):435-50. PubMed ID: 12501127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
    Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
    Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
    Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain and CSF entry of the novel non-nucleoside reverse transcriptase inhibitor, GW420867X.
    Thomas S; Cass L; Prince W; Segal M
    Neuroreport; 2000 Nov; 11(17):3811-5. PubMed ID: 11117496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
    Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
    Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
    Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
    HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers.
    Holdich T; Shiveley L; Sawyer J
    Clin Drug Investig; 2006; 26(5):279-86. PubMed ID: 17163261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
    Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
    Fätkenheuer G; Staszewski S; Plettenburg A; Hackman F; Layton G; McFadyen L; Davis J; Jenkins TM
    AIDS; 2009 Oct; 23(16):2115-22. PubMed ID: 19779321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
    Urata Y; Paintsil E; Cheng YC; Matsuda T; Sevinsky H; Hawthorne D; Bertz R; Hanna GJ; Grasela D; Hwang C
    J Clin Pharmacol; 2014 Jun; 54(6):657-64. PubMed ID: 24374821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.